Early research (Phase 1)Ended earlyNCT02110563
What this trial is testing
Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
Who this might be right for
Solid TumorsMultiple MyelomaNon-Hodgkins Lymphoma+3 more
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company 50